Literature DB >> 26796135

Variable severity of cardiovascular phenotypes in patients with an early-onset form of Marfan syndrome harboring FBN1 mutations in exons 24-32.

Jun Maeda1, Kenjiro Kosaki2, Junko Shiono3, Kazuki Kouno4, Ryo Aeba5, Hiroyuki Yamagishi4.   

Abstract

A subgroup of patients with Marfan syndrome (MFS) who have mutations in exons 24-32 of the FBN1 gene manifests severe atrioventricular valve insufficiency and skeletal problems as early as the neonatal period. These patients usually die in the first 2 years of life, thus a region between exons 24 and 32 of FBN1 is recognized as a critical region for this neonatal form of MFS (nMFS). Here, we report five consecutive patients who manifested a cardiovascular phenotype until infancy with mutations in the critical region for nMFS. Although three of these patients showed severe mitral regurgitation and died before reaching 1 year of age, the remaining two patients survived for over 5 years under medical and/or surgical interventions. Two splicing mutations and one missense mutation were identified in the three deceased patients, whereas two missense mutations were found in the two survivors. Currently, the clinical severity of patients with early-onset MFS harboring mutations in the critical region for nMFS seem to be more variable than ever thought, and intensive treatments are recommended even in this subgroup of patients with MFS.

Entities:  

Keywords:  Cardiovascular phenotype; Early-onset form of Marfan syndrome; FBN1 mutation

Mesh:

Substances:

Year:  2016        PMID: 26796135     DOI: 10.1007/s00380-016-0793-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  26 in total

1.  Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism.

Authors:  Betti Giusti; Maria Cristina Porciani; Tamara Brunelli; Lucia Evangelisti; Sandra Fedi; Gian Franco Gensini; Rosanna Abbate; Guido Sani; Magdi Yacoub; Guglielmina Pepe
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

2.  Central nervous system abnormalities in two cases with neonatal Marfan syndrome with novel mutations in the fibrillin-1 gene.

Authors:  Christopher P Barnett; Gregory J Wilson; David A Chiasson; Gil J Gross; Aleksander Hinek; Cynthia Hawkins; David Chitayat
Journal:  Am J Med Genet A       Date:  2010-09       Impact factor: 2.802

3.  Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

Authors:  Olivier Milleron; Florence Arnoult; Jacques Ropers; Philippe Aegerter; Delphine Detaint; Gabriel Delorme; David Attias; Florence Tubach; Sophie Dupuis-Girod; Henry Plauchu; Martine Barthelet; Francois Sassolas; Nicolas Pangaud; Sophie Naudion; Julie Thomas-Chabaneix; Yves Dulac; Thomas Edouard; Jean-Eric Wolf; Laurence Faivre; Sylvie Odent; Adeline Basquin; Gilbert Habib; Patrick Collignon; Catherine Boileau; Guillaume Jondeau
Journal:  Eur Heart J       Date:  2015-05-02       Impact factor: 29.983

4.  Three novel fibrillin mutations in exons 25 and 27: classic versus neonatal Marfan syndrome.

Authors:  M Wang; J Y Wang; J Cisler; K Imaizumi; B K Burton; M C Jones; J J Lamberti; M Godfrey
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

5.  Atenolol versus losartan in children and young adults with Marfan's syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lynn A Sleeper; Anji T Yetman; Timothy J Bradley; Steven D Colan; Gail D Pearson; E Seda Selamet Tierney; Jami C Levine; Andrew M Atz; D Woodrow Benson; Alan C Braverman; Shan Chen; Julie De Backer; Bruce D Gelb; Paul D Grossfeld; Gloria L Klein; Wyman W Lai; Aimee Liou; Bart L Loeys; Larry W Markham; Aaron K Olson; Stephen M Paridon; Victoria L Pemberton; Mary Ella Pierpont; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; Angela M Sharkey; Mario P Stylianou; Stephanie Burns Wechsler; Luciana T Young; Lynn Mahony
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

6.  Novel exon skipping mutation in the fibrillin-1 gene: two 'hot spots' for the neonatal Marfan syndrome.

Authors:  P Booms; J Cisler; K R Mathews; M Godfrey; F Tiecke; U C Kaufmann; U Vetter; C Hagemeier; P N Robinson
Journal:  Clin Genet       Date:  1999-02       Impact factor: 4.438

7.  Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes.

Authors:  I Schrijver; W Liu; T Brenn; H Furthmayr; U Francke
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

8.  Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40.

Authors:  F Tiecke; S Katzke; P Booms; P N Robinson; L Neumann; M Godfrey; K R Mathews; M Scheuner; G K Hinkel; R E Brenner; H H Hövels-Gürich; C Hagemeier; J Fuchs; F Skovby; T Rosenberg
Journal:  Eur J Hum Genet       Date:  2001-01       Impact factor: 4.246

Review 9.  Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database.

Authors:  Gwenaëlle Collod-Béroud; Saga Le Bourdelles; Lesley Ades; Leena Ala-Kokko; Patrick Booms; Maureen Boxer; Anne Child; Paolo Comeglio; Anne De Paepe; James C Hyland; Katerine Holman; Ilkka Kaitila; Bart Loeys; Gabor Matyas; Lieve Nuytinck; Leena Peltonen; Terhi Rantamaki; Peter Robinson; Beat Steinmann; Claudine Junien; Christophe Béroud; Catherine Boileau
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

10.  Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study.

Authors:  Michael D Pettersen; Wei Du; Mary Ellen Skeens; Richard A Humes
Journal:  J Am Soc Echocardiogr       Date:  2008-04-11       Impact factor: 5.251

View more
  6 in total

Review 1.  Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome.

Authors:  Josephina A N Meester; Aline Verstraeten; Dorien Schepers; Maaike Alaerts; Lut Van Laer; Bart L Loeys
Journal:  Ann Cardiothorac Surg       Date:  2017-11

2.  Early-Onset Marfan Syndrome: A Case Series.

Authors:  Mohanageetha Ardhanari; Deborah Barbouth; Sethuraman Swaminathan
Journal:  J Pediatr Genet       Date:  2018-11-02

3.  NGS analysis in Marfan syndrome spectrum: Combination of rare and common genetic variants to improve genotype-phenotype correlation analysis.

Authors:  Davide Gentilini; Antonino Oliveri; Teresa Fazia; Alessandro Pini; Susan Marelli; Luisa Bernardinelli; Anna Maria Di Blasio
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 4.  The fibrillinopathies: New insights with focus on the paradigm of opposing phenotypes for both FBN1 and FBN2.

Authors:  Silke Peeters; Pauline De Kinderen; Josephina A N Meester; Aline Verstraeten; Bart L Loeys
Journal:  Hum Mutat       Date:  2022-04-28       Impact factor: 4.700

5.  Acromelic dysplasias: how rare musculoskeletal disorders reveal biological functions of extracellular matrix proteins.

Authors:  Sarah Stanley; Zerina Balic; Dirk Hubmacher
Journal:  Ann N Y Acad Sci       Date:  2020-09-02       Impact factor: 5.691

Review 6.  Cardiomyopathy in Genetic Aortic Diseases.

Authors:  Laura Muiño-Mosquera; Julie De Backer
Journal:  Front Pediatr       Date:  2021-07-15       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.